Disease-modifying therapy for multiple sclerosis

Perspectives
    ()

    sporsmal_grey_rgb
    Article

    High-efficacy therapy from the time of diagnosis substantially improves the prognosis for multiple sclerosis. The national guidelines on MS nevertheless recommend less effective therapy for many patients, and must be updated in pace with medical advances. We consider in the following how multiple sclerosis should be treated.

    In multiple sclerosis (MS), the immune system attacks the central nervous system through lymphocytes initiating local inflammation. Clinically this gives rise to fully or partly transient neurological deficits, known as relapsing-remitting multiple sclerosis (RRMS). If untreated, the relapses convert to gradually increasing functional deficits, termed secondary progressive disease, when the neurodegeneration is no longer driven by lymphocyte attacks.

    Disease-modifying MS therapy suppresses lymphocyte attacks. The effect is pronounced early in the course of the disease, and abates with the development of progressive disease (1). Early, high-efficacy therapy for relapsing-remitting multiple sclerosis slows the advance of progressive functional impairment in the majority of patients (2). Conversely, a more defensive escalation strategy, with gradually increasing therapeutic intensity, leads to progressive functional decline in the majority (3). This therapeutic principle used to be the dominant one (4), and is partly supported by the national guidelines on MS, which several of the authors were involved in drawing up in 2017 (5).

    Therapeutic effects

    Therapeutic effects

    The effect of relevant drugs on relapse frequency is shown in Table 1 (6–9). Owing to variation in the comparator and disease activity prior to the start of the study, it is not clear which drug is the most effective. Network-based analyses, as in the Norwegian Institute of Public Health's method evaluation of 2019, may shed light on this (10), but are usually based on short studies of selected patients. Real-world registry-based studies with long follow-up times provide clinically relevant evidence of long-term therapeutic efficacy and risk (11).

    Table 1

    Key data on disease-modifying drugs for relapsing-remitting multiple sclerosis (RRMS)

    Reduction of relapses in phase III trials ( 6 )

    Administration ( 6 )

    Relevant comorbidity

    Appropriate for those wanting children ( 7 , 8 )

    Significant reduction in response to vaccine ( 9 )

    Approved indication

    Approved by Decision Forum

    Alemtuzumab1

    50–54 % vs interferon beta

    Intravenously annually for two years

    Immunodeficiency Vascular disease
    Autoimmunity

    Partial

    Probably transient

    Very active RRMS

    Yes

    Ocrelizumab

    46–47 % vs interferon beta

    Intravenously semi-annually

    Immunodeficiency
    Latent hepatitis

    Yes

    Yes

    RRMS and PPMS

    No

    Ofatumumab

    50–60 % vs teriflunomide

    Subcutaneously monthly

    Immunodeficiency
    Latent hepatitis

    No

    Probably yes

    RRMS

    In process

    Rituximab

    Not conducted

    Intravenously semi-annually

    Immunodeficiency
    Latent hepatitis

    Yes

    Yes

    Not applied for

    Yes, to be registered in MS registry

    Natalizumab

    68 % vs placebo

    Intravenously monthly

    JCV carrier

    Partial

    No

    Very active RRMS

    Not for new patients

    Cladribine

    55 % vs placebo

    By mouth annually for two years

    Immunodeficiency

    Yes

    Unknown

    Highly active RRMS

    Yes

    Fingolimod

    42 % and 52 % vs placebo 52 % vs Interferon-beta

    By mouth daily

    Immunodeficiency
    Hypertension
    AV block
    Diabetes

    No

    Yes

    Highly active RRMS, also children

    Not for new patients

    Reduction of relapses in phase III trials ( 4 , 17 )

    Administration ( 4 , 17 )

    Relevant comorbidity

    Appropriate when wanting children ( 18 , 19 )

    Significant reduction in response to vaccine ( 20 )

    Approved indication

    Approved by decision-making forum

    Ozanimod

    39 % and 49 % vs interferon beta

    By mouth daily

    Immunodeficiency
    Hypertension
    AV block

    No

    Probably yes

    Active RRMS

    Yes

    Dimethyl fumarate

    44–53 % vs placebo

    By mouth daily

    Immunodeficiency
    Effect on psoriasis

    No

    No

    RRMS

    Yes

    Teriflunomide

    32 % vs placebo 18 % vs interferon beta

    By mouth daily

    Immunodeficiency
    Hypertension
    Liver disease

    No

    No

    RRMS

    Yes

    Interferon-beta

    19–32 % vs placebo

    Self-injection every 2 to 14 days

    Depression

    Yes

    No

    RRMS, CIS, SPMS

    Yes

    Glatiramer acetate

    29–34 % vs placebo

    Self-injection from daily to 3 x weekly

    No

    Yes

    No

    RRMS

    Yes

    1Because of its adverse effects profile, the Pharmaceutical Purchasing Cooperation's specialist team does not class alemtuzumab on the same level as other MS therapy.

    Both network-based analyses and longitudinal studies indicate that natalizumab, alemtuzumab, ocrelizumab and ofatumumab are among the most effective drugs. Phase II trials with frequent MRI scans also show them to have a rapid onset of action (11). Cladribine, fingolimod and ozanimod are also more effective than the first-line drugs interferon beta, glatiramer acetate and teriflunomide (11).

    In the absence of phase III trials, longitudinal studies and phase II trials form the evidence base for the use of rituximab for multiple sclerosis (12). Like ocrelizumab and ofatumumab, rituximab is a monoclonal antibody that kills B-lymphocytes. Rituximab is more immunogenic, but except in rare cases of serum sickness, the significance of this is uncertain (13).

    The long-term effect on the development of disability is more important than the relapse frequency, but more difficult to establish because the pivotal studies only last for two years. However, registry-based and follow-up studies show that the effect on relapses corresponds to the effect on the development of disability (2, 3). Studies of brain atrophy and biomarkers for neuronal injury support this (14). An overall assessment indicates that natalizumab, alemtuzumab, ocrelizumab, ofatumumab, rituximab, cladribine, fingolimod and ozanimod are highly effective for RRMS.

    Risk stratification

    Risk stratification

    High-efficacy drugs are generally tolerated better than less effective drugs, but may entail greater risk. Alemtuzumab stands out in that almost half of patients develop Grave's disease or another autoimmune disorder. Moreover, opportunistic infections and acute angiopathy have caused deaths a short time after treatment (15). The Norwegian Hospital Procurement Trust's specialist team therefore does not class alemtuzumab with other MS treatment. Natalizumab can cause progressive multifocal leukoencephalopathy (PML) in carriers of JC virus. Other high-efficacy MS drugs, not least rituximab and ocrelizumab, reduce response to vaccines and increase the risk of infections (16).

    The possibility of risk stratification has now substantially reduced the risk associated with high-efficacy treatment

    The risk of progressive multifocal leukoencephalopathy in connection with natalizumab can be almost eliminated by not treating carriers of JC virus, and is substantially reduced for others by increasing the intervals between infusions (17). The risk associated with the other drugs can be reduced by taking comorbidity into account when selecting drugs (Table 1).

    None of the MS drugs appear to appreciably increase the risk of COVID-19 infection. In registry-based studies, rituximab and ocrelizumab are associated with an increased need for intensive care and ventilation, but not with increased mortality (18).

    Treatment strategies

    Treatment strategies

    When the association between natalizumab and progressive multifocal leukoencephalopathy was revealed in 2006, at-risk patients could not be identified. The escalation strategy was then justified on the basis of the precautionary principle. The possibility of risk stratification has now substantially reduced the risk associated with high-efficacy treatment. Clinical experience also indicates that less effective treatment is often halted because of adverse effects or lack of efficacy. It takes several months for a new treatment to become fully effective. Patients age and undergo more inflammatory episodes, and are at increased risk of complications and reduced efficacy by the time high-efficacy treatment is finally initiated.

    An alternative strategy is to recommend high-efficacy treatment if prognostic factors such as relapse rate, number of lesions detected by MRI and involvement of the brainstem and spinal cord indicate a severe course. Such factors largely reflect previous disease activity. Even if they predict the prognosis at group level, it is uncertain whether they predict treatment benefit at the individual level. The long-term prognosis at the time of diagnosis is normally so uncertain that prognostic factors do not justify starting less effective treatment.

    Pivotal studies, longitudinal studies and effect on biomarkers all indicate that early treatment with high-efficacy agents results in the greatest benefit and least risk over time (2, 3, 19, 20). As a general rule we therefore recommend immediate initiation of high-efficacy drugs in cases of RRMS (Figure 1). Potential exceptions are patients who for reasons of age or comorbidity are particularly vulnerable to harmful treatment effects (Table 1), or where many years of observation since symptom onset point to a benign disease course.

    Choice of high-efficacy drug

    Choice of high-efficacy drug

    The differences in efficacy, risk and other treatment-related burden among most high-efficacy drugs are uncertain. The choice of drug therefore tends to depend on other factors (Table 1).

    In cases of pronounced inflammatory activity, we recommend drugs with a fast onset effect, such as natalizumab, ocrelizumab and rituximab.

    Multiple sclerosis often affects young women. Many pregnancies are not planned, and changes in treatment increase the risk of disease activity. Fertile women should therefore be offered treatment that makes pregnancy possible without a break in treatment.

    The differences in efficacy, risk and other treatment-related stress among most high-efficacy drugs are uncertain. The choice of drug therefore tends to depend on other factors

    The effects of cladribine, ocrelizumab and rituximab last long after they have been eliminated from the body, and they are therefore suitable for fertile women. Alemtuzumab has the same property, but the risk of Grave's disease means that close monitoring is required during pregnancy. Natalizumab can be used up to the last trimester. Breaks in treatment may cause severe disease breakthrough nonetheless. Fingolimod and ozanimod are probably teratogenic, and breaks in treatment may result in severe disease flare-ups. They are therefore less suitable for fertile women.

    Comorbidity such as immunodeficiency, chronic infections, liver disease, cardiovascular disease, hypertension and uveitis influence the choice of therapy (Table 1). Natalizumab results in limited immunosuppression and may be suitable for patients with immunodeficiency or chronic infections. Some MS drugs are also effective against other diseases; for instance, natalizumab and ozanimod are effective against inflammatory bowel disease and dimethyl fumarate is effective against psoriasis.

    Discontinuing treatment

    Discontinuing treatment

    In the past it has been usual to discontinue immunomodulatory treatment after transition to secondary progressive disease. However, with high-efficacy treatment it is difficult to know whether patients with slow progressive functional decline still have latent RR disease.

    Discontinuation of natalizumab, fingolimod and ozanimod is associated with a substantial risk of serious relapses, and great caution should therefore be exercised when discontinuing these drugs. On the other hand, the risks associated with immunosuppression increase with age, and approved dosage is based on studies of patients under the age of 60. Observational studies indicate that the effects of natalizumab and rituximab remain the same when inter-dose intervals are increased (13, 21) but there is a general lack of reliable evidence as to when and how immunomodulatory treatment should be tapered, and patients must always be monitored clinically and radiologically.

    As alemtuzumab and cladribine are not usually redosed, the question of discontinuation of treatment is avoided.

    Haematopoietic stem cell transplantation

    Haematopoietic stem cell transplantation

    In open-label studies, high-dose chemotherapy with autologous haematopoietic stem cell transplantation reduces disease activity in RRMM very effectively (22). The risk of serious complications is low in younger patients who are otherwise healthy. In Norway, the treatment is offered at Haukeland University Hospital on strict indication, mainly as part of a randomised trial. The treatment may be relevant for more patients in the future.

    Progressive multiple sclerosis

    Progressive multiple sclerosis

    Phase III trials show that ocrelizumab and siponimod are moderately effective for primary and secondary progressive disease, primarily in patients with relapses or new MRI lesions (23). These drugs have not been approved by the Decision Forum. As their efficacy is probably due to suppression of lymphocyte attacks, we recommend attempting therapy with other high-efficacy drugs for younger patients with rapid clinical exacerbation, relapses or MRI activity.

    Financial and regulatory aspects

    Financial and regulatory aspects

    Expenditure on MS drugs was almost a billion kroner in 2019 (Anne Helen Ognøy, Norwegian Hospital Procurement Trust, personal communication). The prices are negotiated by the Norwegian Hospital Procurement Trust and are exempt from public disclosure. Following a health economics assessment as part of the Norwegian Institute of Public Health's method evaluation, the Decision Forum decided in 2019 to halt the start-up of fingolimod and natalizumab, although the costs did not differ from those of drugs the specialist community judges to be equivalent.

    Individually tailored high-efficacy treatment should be the general rule

    The Decision Forum also declined to introduce siponimod and ocrelizumab. They have subsequently rejected all applications from the specialist community for exceptions for subgroups of patients, but have introduced rituximab, which costs about a twentieth as much as ocrelizumab. In 2019 rituximab was the drug most widely used in Norway for multiple sclerosis (8). Large regional differences may reflect different attitudes to providing treatment outside of the approved indications and without the support of phase III trials. Comparative studies are now being conducted with ocrelizumab and cladribine. The approved indication for other high-efficacy MS drugs is generally narrower than that applied in clinical practice (Table 1). Thus treatment outside of an approved indication is widespread and increasing.

    Conclusion

    Conclusion

    Swift and effective treatment of relapsing-remitting multiple sclerosis substantially improves the prognosis. Individually adapted high-efficacy treatment should be the general rule. The national guidelines on MS must be revised continuously in pace with developments in the discipline.

    PDF
    Print
    Reply to article

    Recent Articles

    Made by Ramsalt Using Ramsalt Media